comprehensive -WSS

comprehensive

author：explore 2025-09-29 13:09:20 - browse：3

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： How CO2 helps viruses stay alive longer in the air

WSS

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Venture capitalist Bob Kocher on the state of digital health

BD to buy Edwards patient monitoring unit for $4.2 billion

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

FDA approves Moderna’s RSV vaccine, its second licensed product

Wikipedia

comprehensive

Wikipedia

Apple is now the first public company to be valued at $3 trillion

Illumina board agrees to spin off Grail, as divestment plans proceed

Malaria cases in Florida and Texas: Here’s what you need to know

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Malaria cases in Florida and Texas: Here’s what you need to know

Elevance PBM president out as customers face prescription chaos

In age of alternative facts, a scholarly course on calling out crap

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Hepatitis C has a cure — but many Americans still lack access to it

BD to buy Edwards patient monitoring unit for $4.2 billion

entertainment

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Bird flu: Don't repeat Covid's 'health versus the economy' framing

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Helping hospitals and community health centers plan for resilience

Criminal prosecution for violating HIPAA: an emerging threat

Congress needs to close a vaccine

hotspot

knowledge

focus

explore